ArticleClinical rheumatology2025
Validation and cross-cultural adaptation of the Thai version of the Systemic Sclerosis Health Assessment Questionnaire.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Scleroderma Health Assessment Questionnaire (S-HAQ), including the Disability Index (HAQ-DI) and six-symptom visual analog scales (VAS), assesses functional ability in systemic sclerosis (SSc). The Thai HAQ-DI has been validated, but not the S-HAQ VAS.
objectiveWe aim to translate and culturally adapt the VAS for symptoms in S-HAQ and assess its validity and reliability.
methodThe six VAS items, which assess pain, gastrointestinal symptoms, respiratory symptoms, Raynaud's phenomenon (RP), digital ulcers (DU), and overall disease activity interfering with daily activities, were translated into Thai and validated. Thirty SSc patients completed the translated questionnaire twice, with a one-week interval. Intraclass correlation (ICC) was used for test-retest reliability, and Spearman correlation was used to test the reliability of the associated clinical parameters and the S-HAQ VAS.
resultFor the validity testing, the VAS for pain, respiratory symptoms, RP, DU, and overall disease activity showed significant correlations with the modified Rodnan skin score (mRSS) (Rho = 0.508, 0.550, 0.474, 0.492, and 0.557, respectively) and with the EuroQol visual analog scale (EQ VAS) (Rho = - 0.652, - 0.697, - 0.568, - 0.581, and - 0.668, respectively). Additionally, the World Health Organization functional class demonstrated significant correlations with both the VAS overall disease activity and the HAQ-DI (Rho = 0.473 and 0.460, respectively). The HAQ-DI showed significant correlations with all the S-HAQ VAS questions. The reliability testing indicated a strong ICC between two testing sessions for each VAS item in the S-HAQ, with coefficient values ranging from 0.777 to 0.940.
conclusionThis study substantiates the utility of the Thai S-HAQ VAS as a valid measure for assessing function and disability in patients with SSc. The translated Thai version of the S-HAQ VAS exhibits high reliability, demonstrated by strong ICC between two testing sessions. Key Points • The Thai version of the Scleroderma Health Assessment Questionnaire (S-HAQ) visual analog scale (VAS) was successfully translated and culturally adapted. It provides a reliable and valid tool for assessing systemic sclerosis (SSc) symptoms and disability in native Thai patients. • Strong test-retest reliability was demonstrated for all six VAS items, with intraclass correlation (ICC) values ranging from 0.777 to 0.940 and the validity testing showed significant correlations between S-HAQ VAS scores and clinical parameters, including mRSS, EQ-VAS, and WHO functional class. • The availability of this validated tool enables Thai researchers to participate in international SSc clinical trials and comparative studies using standardized outcome measures, enhancing global research collaboration.
Indexed as
Identifiers
40593370What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.